Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Subscribe To Our Newsletter & Stay Updated
